RecruitingNot Applicable

Outcomes of PFA Vs. RFA for Patients with PSVT: a Retrospective and Propensity Score Matching Study

China428 participantsStarted 2022-10-11

Plain-language summary

The goal of this retrospective study is to compare the long-term follow-up outcomes of pulses field ablation (PFA) Vs. radiofrequency ablation (RFA) for the patients with paroxysmal supraventricular tachycardia (PSVT). The main question to answer is: Does the PFA was more effecient and safer that RFA for treatment of PSVT during procedure and after 1-year follow-up? Researchers will compare the acute and long-term efficiency and safety between PFA and RFA. 1. Recieved PFA or RFA 1 year ago 2. Finish the visit to the clinic at 1, 3, 6, 12 months for examinations and blood testings 3. Patients recieved PFA and PFA under propensity matched comparison according to differen variety of PSVT

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with symptomatic PSVT including: atrioventricular nodal re-entrant tachycardia (AVNRT), atrioventricular re-entrant tachycardia (AVRT);
✓. Age range: 18 years old ≤ age ≤ 80 years old, with no gender restriction;
✓. Willing to receive the examinations and testings during one year follow-up required by the protocol;
✓. Voluntary signed informed consent.

Exclusion criteria

✕. Organic heart disease;
✕. History of cardiac surgery;
✕. Previous failed ablation of PSVT;
✕. Presence of any implants, such as a permanent pacemaker;
✕. Patients with invasive systemic infections or advanced malignant tumors;
✕. Contraindications for septal puncture or retrograde transaortic access surgery;

What they're measuring

Acute and long-term follow-up success rate

Timeframe: 15 minutes post ablation for acute sussess and one year for follow-up success

Incidence of intraoperative and long-term serious adverse events

Timeframe: 24 hours post ablation for intraoperative serious adverse events and one year for follow-up serious adverse events

Trial details

NCT IDNCT06573853

SponsorCaijie Shen

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-06-30

Contact for this trial

Caijie Shen, MD,PhD

8615258258126 shenzihai1101@126.com

View on ClinicalTrials.gov More Paroxysmal Supraventricular Tachycardia trials